Trovagene announces pricing of public offering of common stock
09/02/2015 12:50
Trovagene, Inc., a developer of cell-free molecular diagnostics, announced the pricing of an underwritten public offering of 4,444,444 shares of its common stock. The gross proceeds to Trovagene from this offering are expected to be approximately USD 20 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Trovagene. The offering is expected to close on or about February 11, 2015, subject to customary closing conditions. Trovagene intends to use the net proceeds from this offering to fund its research and development activities and for working capital and other general corporate purposes. Piper Jaffray & Co. is acting as sole book-running manager and Janney Montgomery Scott LLC, Maxim Group LLC and Cantor Fitzgerald & Co. are acting as co-managers for the offering.
09/02/2015 12:50
Trovagene, Inc., a developer of cell-free molecular diagnostics, announced the pricing of an underwritten public offering of 4,444,444 shares of its common stock. The gross proceeds to Trovagene from this offering are expected to be approximately USD 20 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Trovagene. The offering is expected to close on or about February 11, 2015, subject to customary closing conditions. Trovagene intends to use the net proceeds from this offering to fund its research and development activities and for working capital and other general corporate purposes. Piper Jaffray & Co. is acting as sole book-running manager and Janney Montgomery Scott LLC, Maxim Group LLC and Cantor Fitzgerald & Co. are acting as co-managers for the offering.
